Patient activation for drug reviewing by telemedicine

Not Applicable

• Conditions: Patient activation; Not Applicable

• Registration Number: ISRCTN14366792
• Lead Sponsor: niversity of Zurich

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-29
• Study Completion: 2021-05-31
• Last Update Posted: 5 August 2022

Recruitment & Eligibility

• Status: Stopped
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

1. Patients insured at SWICA
2. German-speaking
3. 60 years or older
4. Using at least five different drugs, at least three original packages over the last 12 months and at least one month distance in between. Exception of this 12 months rule and included in the data are androgens, vitamin B12, antineoplastic and immunemodulating agents and drugs for treating osteoporosis. Excluded drugs are topical (including dermatologicals, nasal-, throat-, cough and cold preparations, transdermal opioids), intravenous and homeopathic drugs, vaccines, surgical dressings, contrast agents as well as products from these pharmaceutical companies (Ceres®, Similisan®, Omnida®, Spagyros® and Vogel®)
5. Signed Informed Consent after being informed

Exclusion Criteria

Patients insured at SWICA with a GP guided healthcare plan

Study & Design

• Study Type: Interventional
• Study Design: Not specified